A new risk model uses objective clinical data to predict cure or relapse in Hodgkin lymphoma, with future plans to guide treatment and survivorship care.
Andrew M. Evens, DO, MBA, MSc
Advertisement
Andrew Evens, DO, MBA, MSc, is the Deputy Director for Clinical Services and Chief Physician Officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center; System Director of Medical Oncology and Oncology Lead, RWJBarnabas Health Medical Group; and Associate Vice Chancellor for Clinical Innovation and Data Analytics, Rutgers Biomedical and Health Sciences.
Articles by Andrew M. Evens, DO, MBA, MSc
Andrew Evens, DO, MBA, MSc, discusses a modern way of stratifying risk in patients with early-stage Hodgkin lymphoma.
Andrew Evens, DO, MBA, MSc, discusses the HOLISTIC consortium, which aims to gather and harmonize global Hodgkin lymphoma data from clinical trials and registries.
Andrew M. Evens, DO, MSc, discusses the significance of the results from the phase III ECHELON-1 trial in which patients with stage III/IV classical Hodgkin lymphoma were treated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine.
Advertisement
Latest Updated Articles
Brentuximab Vedotin Adds Benefit to A+AVD Therapy in cHLPublished: December 3rd 2019 | Updated:
Dr Evens on Personalizing Therapy for Patients with Hodgkin LymphomaPublished: July 2nd 2025 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
